BMRN Annual Accounts Receivable
$633.70 M
+$172.39 M+37.37%
31 December 2023
Summary:
As of January 19, 2025, BMRN annual accounts receivable is $633.70 million, with the most recent change of +$172.39 million (+37.37%) on December 31, 2023. During the last 3 years, it has risen by +$185.35 million (+41.34%). BMRN annual accounts receivable is now at all-time high.BMRN Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BMRN Quarterly Accounts Receivable
$777.55 M
+$86.31 M+12.49%
30 September 2024
Summary:
As of January 19, 2025, BMRN quarterly accounts receivable is $777.55 million, with the most recent change of +$86.31 million (+12.49%) on September 30, 2024. Over the past year, it has increased by +$143.84 million (+22.70%). BMRN quarterly accounts receivable is now at all-time high.BMRN Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BMRN Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +37.4% | +22.7% |
| 3 y3 years | +41.3% | +30.0% |
| 5 y5 years | +85.0% | +30.0% |
BMRN Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +69.7% | at high | +108.2% |
| 5 y | 5-year | at high | +69.7% | at high | +108.2% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
BioMarin Pharmaceutical Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $777.55 M(+12.5%) |
| June 2024 | - | $691.23 M(+8.5%) |
| Mar 2024 | - | $637.16 M(+0.5%) |
| Dec 2023 | $633.70 M(+37.4%) | $633.70 M(+10.7%) |
| Sept 2023 | - | $572.50 M(-6.2%) |
| June 2023 | - | $610.22 M(+2.1%) |
| Mar 2023 | - | $597.91 M(+29.6%) |
| Dec 2022 | $461.32 M(+23.5%) | $461.32 M(+9.9%) |
| Sept 2022 | - | $419.62 M(-10.1%) |
| June 2022 | - | $466.51 M(+8.5%) |
| Mar 2022 | - | $430.15 M(+15.2%) |
| Dec 2021 | $373.40 M(-16.7%) | $373.40 M(-0.4%) |
| Sept 2021 | - | $374.94 M(-11.7%) |
| June 2021 | - | $424.42 M(+7.2%) |
| Mar 2021 | - | $396.10 M(-11.7%) |
| Dec 2020 | $448.35 M(+18.8%) | $448.35 M(+8.9%) |
| Sept 2020 | - | $411.71 M(+8.0%) |
| June 2020 | - | $381.21 M(-3.8%) |
| Mar 2020 | - | $396.38 M(+5.0%) |
| Dec 2019 | $377.40 M(+10.1%) | $377.40 M(-6.3%) |
| Sept 2019 | - | $402.97 M(+6.8%) |
| June 2019 | - | $377.15 M(-4.1%) |
| Mar 2019 | - | $393.43 M(+14.8%) |
| Dec 2018 | $342.63 M(+31.1%) | $342.63 M(-10.9%) |
| Sept 2018 | - | $384.34 M(+5.7%) |
| June 2018 | - | $363.57 M(+14.2%) |
| Mar 2018 | - | $318.39 M(+21.8%) |
| Dec 2017 | $261.37 M(+21.4%) | $261.37 M(+3.8%) |
| Sept 2017 | - | $251.89 M(+5.7%) |
| June 2017 | - | $238.34 M(+3.5%) |
| Mar 2017 | - | $230.25 M(+7.0%) |
| Dec 2016 | $215.28 M(+30.5%) | $215.28 M(-0.3%) |
| Sept 2016 | - | $215.89 M(+0.8%) |
| June 2016 | - | $214.16 M(+18.5%) |
| Mar 2016 | - | $180.75 M(+9.6%) |
| Dec 2015 | $164.96 M(+14.2%) | $164.96 M(+10.7%) |
| Sept 2015 | - | $148.95 M(-20.0%) |
| June 2015 | - | $186.08 M(+5.9%) |
| Mar 2015 | - | $175.74 M(+21.6%) |
| Dec 2014 | $144.47 M(+22.6%) | $144.47 M(+19.0%) |
| Sept 2014 | - | $121.39 M(-0.7%) |
| June 2014 | - | $122.28 M(+10.7%) |
| Mar 2014 | - | $110.46 M(-6.2%) |
| Dec 2013 | $117.82 M | $117.82 M(-5.5%) |
| Sept 2013 | - | $124.75 M(+8.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2013 | - | $115.06 M(-4.4%) |
| Mar 2013 | - | $120.34 M(+10.3%) |
| Dec 2012 | $109.07 M(+4.0%) | $109.07 M(-7.0%) |
| Sept 2012 | - | $117.29 M(+16.4%) |
| June 2012 | - | $100.75 M(-4.8%) |
| Mar 2012 | - | $105.83 M(+0.9%) |
| Dec 2011 | $104.84 M(+21.1%) | $104.84 M(-2.1%) |
| Sept 2011 | - | $107.06 M(+0.4%) |
| June 2011 | - | $106.61 M(+0.4%) |
| Mar 2011 | - | $106.20 M(+22.7%) |
| Dec 2010 | $86.58 M(+17.7%) | $86.58 M(+10.0%) |
| Sept 2010 | - | $78.73 M(+1.4%) |
| June 2010 | - | $77.68 M(-6.0%) |
| Mar 2010 | - | $82.61 M(+12.3%) |
| Dec 2009 | $73.54 M(+35.4%) | $73.54 M(+7.5%) |
| Sept 2009 | - | $68.38 M(-5.8%) |
| June 2009 | - | $72.58 M(+18.3%) |
| Mar 2009 | - | $61.35 M(+13.0%) |
| Dec 2008 | $54.30 M(+219.9%) | $54.30 M(+6.2%) |
| Sept 2008 | - | $51.13 M(-2.0%) |
| June 2008 | - | $52.16 M(+10.4%) |
| Mar 2008 | - | $47.25 M(+178.4%) |
| Dec 2007 | $16.98 M(+15.7%) | $16.98 M(+6.3%) |
| Sept 2007 | - | $15.97 M(+0.4%) |
| June 2007 | - | $15.90 M(+9.5%) |
| Mar 2007 | - | $14.53 M(-1.0%) |
| Dec 2006 | $14.67 M(+150.3%) | $14.67 M(+12.8%) |
| Sept 2006 | - | $13.00 M(+18.8%) |
| June 2006 | - | $10.95 M(+46.1%) |
| Mar 2006 | - | $7.49 M(+27.9%) |
| Dec 2005 | $5.86 M(+44.8%) | $5.86 M(+10.0%) |
| Sept 2005 | - | $5.33 M(+85.6%) |
| June 2005 | - | $2.87 M(+56.8%) |
| Mar 2005 | - | $1.83 M(-54.8%) |
| Dec 2004 | $4.05 M(+30.7%) | $4.05 M(+3300.8%) |
| Sept 2004 | - | $119.00 K(-97.4%) |
| June 2004 | - | $4.61 M(+97.8%) |
| Sept 2002 | - | $2.33 M(+9.2%) |
| June 2002 | - | $2.13 M(-63.7%) |
| Mar 2002 | - | $5.89 M(+90.2%) |
| Dec 2001 | $3.10 M(+72.1%) | $3.10 M(+210.8%) |
| Sept 2001 | - | $996.00 K(+37.0%) |
| June 2001 | - | $727.00 K(-3.6%) |
| Mar 2001 | - | $754.00 K(-58.1%) |
| Dec 2000 | $1.80 M(-27.0%) | $1.80 M(-27.0%) |
| Dec 1999 | $2.47 M | $2.47 M |
FAQ
- What is BioMarin Pharmaceutical annual accounts receivable?
- What is the all time high annual accounts receivable for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical annual accounts receivable year-on-year change?
- What is BioMarin Pharmaceutical quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical quarterly accounts receivable year-on-year change?
What is BioMarin Pharmaceutical annual accounts receivable?
The current annual accounts receivable of BMRN is $633.70 M
What is the all time high annual accounts receivable for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high annual accounts receivable is $633.70 M
What is BioMarin Pharmaceutical annual accounts receivable year-on-year change?
Over the past year, BMRN annual accounts receivable has changed by +$172.39 M (+37.37%)
What is BioMarin Pharmaceutical quarterly accounts receivable?
The current quarterly accounts receivable of BMRN is $777.55 M
What is the all time high quarterly accounts receivable for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high quarterly accounts receivable is $777.55 M
What is BioMarin Pharmaceutical quarterly accounts receivable year-on-year change?
Over the past year, BMRN quarterly accounts receivable has changed by +$143.84 M (+22.70%)